 Heat Biologics Inc NASDAQ: HTBX shares are trading higher on Monday after the company announced the first patient has been treated in its first-in-human clinical trial of PTX-35.Heat Biologics is a U.S.-based immuno-oncology company. It is engaged in developing therapies that activate a patients immune system against cancer utilizing an engineered form of gp96. The groups T cell-stimulating therapeutic vaccine platform technologies, Immune Pan-Antigen Cytotoxic Therapy ImPACT and Combination Pan-Antigen Cytotoxic Therapy ComPACT, form the basis of its product candidates.Through ImPACT, it developed product candidates consisting of live, genetically-modified, irradiated human cancer cells that secrete tumor-associated antigens together with an immune response stimulator called gp96.Heat Biologics shares were trading up 2.88 at 77 cents on Monday. The stock has a 52-week high of 1.26 and a 52-week low of 20 cents.Related Links:Heat Biologics Shares React Amid Circulation Of PatentScope DocSee more from Benzinga Why Five Primes Stock Is Trading Higher Today Why Gaps Stock Is Trading Higher Today Cruise Stocks Fall After Halting Trips From US PortsC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 